EKR Therapeutics Raises $13 Million

EKR Therapeutics Inc., a Cedar Knolls, N.J.-based drug company focused on therapeutics that enhance quality-of-life in acute care settings, has raised over $13 million in Series C funding. Quaker BioVentures led the deal, and was joined by the Garden State Life Sciences Venture fund, the Merrill Lynch Capital Healthcare Finance Group and return backers NewSpring Capital and ESP Equity Partners. www.ekrtx.com